Veracity Capital LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Veracity Capital LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 25.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,585 shares of the company’s stock after selling 1,204 shares during the quarter. Veracity Capital LLC’s holdings in Novo Nordisk A/S were worth $308,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NVO. Verde Capital Management lifted its position in shares of Novo Nordisk A/S by 115.6% during the fourth quarter. Verde Capital Management now owns 23,904 shares of the company’s stock worth $2,056,000 after purchasing an additional 12,815 shares in the last quarter. Red Door Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 167.3% in the 4th quarter. Red Door Wealth Management LLC now owns 9,608 shares of the company’s stock worth $826,000 after buying an additional 6,013 shares in the last quarter. Avior Wealth Management LLC boosted its position in Novo Nordisk A/S by 13.9% in the 4th quarter. Avior Wealth Management LLC now owns 20,597 shares of the company’s stock valued at $1,772,000 after buying an additional 2,511 shares during the last quarter. Wendell David Associates Inc. increased its position in shares of Novo Nordisk A/S by 0.3% during the fourth quarter. Wendell David Associates Inc. now owns 76,847 shares of the company’s stock worth $6,610,000 after acquiring an additional 225 shares during the last quarter. Finally, Traynor Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 4.8% in the fourth quarter. Traynor Capital Management Inc. now owns 320,162 shares of the company’s stock valued at $27,540,000 after purchasing an additional 14,758 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $87.94 on Friday. The stock has a market capitalization of $394.65 billion, a P/E ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The firm’s 50-day moving average price is $95.62 and its two-hundred day moving average price is $115.55. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.